It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates.
The industrials Bullboards have been far from quiet in recent months.
Bombardier (TSX:BBD, Forum) stock is up more than 2 per cent this week, and it has been a good one for the aerospace company. It introduced its new Advanced Avionics Upgrade (AAU) for the Bombardier Vision flight deck.
This is a new avionics software and hardware upgrade to enhance situational awareness and offer advanced visualization features. It is available for in-service Global 5000, Global 6000, Global 5500 and Global 6500 aircraft equipped with the Bombardier Vision flight deck.
The AAU software will see Bombardier’s Combined Vision System, which integrates features of the Synthetic Vision System, and the Enhanced Vision System in a single view to reduce crew workload and streamline situational awareness offering what the company calls “the clearest view through the toughest weather.”
Source: Bombardier.
Important safety and performance-enhancing capabilities with the AAU include:
- Engine Indicating and Crew Alerting System with improved message logic
- Integrated Flight Information System that sets the industry standard for system integration, quantity and quality of information
- Updated weather enhancements with XM/SXM Graphical Weather/DataLink Graphical Weather
- Further improvements to the Electronic Flight Instrument System that provides updates to the head-up display, primary flight display logic and Synthetic Vision System for enhanced operational performance
Montréal-based biopharmaceutical company Theratechnologies Inc. (TSX:TH, Forum) has officially begun enrolling patients for a Phase 1 clinical trial of its lead drug in patients with advanced ovarian cancer.
Patients are being enrolled in all five of its U.S. clinical sites, while a sixth clinical site in Canada is being finalized.
Called sudocetaxel zendusortide, the company’s drug conjugate candidate was developed out of its SORT1+ Technology and is currently linked to docetaxel, which is a commonly used cytoxic agent to treat cancers.
The SORT1+ Technology platform is a platform of proprietary peptides for cancer drug development that is targeting SORT1 receptors.
What the “Buzz”
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get “Buzz on the Bullboards” delivered to your inbox every Thursday!
Buzz on the Bullboards | Sign Up Here
It is estimated that the SORT1 receptor is found in 40 per cent to 90 per cent of endometrial, ovarian, colorectal, triple-negative breast and pancreatic cancers.
Those involved in studying and learning about the effects of cannabis use have said the surface has been merely scratched on what we have learned, and new studies are revealing unique uses.
MediPharm Labs’ (TSX:LABS, Forum) subsidiary published a study on medical cannabis’ impacts on anxiety and depression in fibromyalgia patients.
The study, “Self-Reported Effects of Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series,” was published by Harvest Medicine in the peer-reviewed American Journal of Endocannabinoid Medicine.
This is the largest peer reviewed published study of its kind on fibromyalgia and cannabis, with more than 800 patient assessments.
Between baseline and follow-up appointments, 75 per cent of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.
Anxiety scores were improved in 22 per cent of those patients reporting mild-moderate severity, and in 48 per cent of patients reporting severe anxiety.
The study data shows that medical cannabis could play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety.
Next week is a shorter trading week, so it might be a bit quieter. At the same time, the discussions on the Bullboards will be alive and kicking, especially if some companies try to tuck some bad news into a long weekend, so come back next week to find out what the community is talking about. For previous editions of Buzz on the Bullboards: click here.
Join the discussion: Find out what everybody’s saying about public companies and hot topics about stocks at Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, click here.